Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.60 |
| ▸ | TACR2 | P21452 | 14/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408809 | 1.00 | UTS2R (0.60) | UTS2RTACR2NPY5RFPR2S1PR1 | |
| SCHEMBL5406754 | 0.94 | TACR2 (0.62) | UTS2RTACR2NPY5RFPR2 | |
| SCHEMBL5406771 | 0.94 | TACR2 (0.62) | UTS2RTACR2NPY5RFPR2 | |
| SCHEMBL14543803 | 0.91 | NPY5R (0.52) | UTS2RTACR2NPY5RS1PR1 | |
| SCHEMBL5411794 | 0.91 | TACR2 (0.57) | UTS2RTACR2NPY5RFPR2S1PR1 | |
| SCHEMBL5411803 | 0.91 | TACR2 (0.57) | UTS2RTACR2NPY5RFPR2S1PR1 | |
| SCHEMBL5414423 | 0.88 | TACR2 (0.58) | TACR2NPY5RFPR2S1PR1 | |
| SCHEMBL5414433 | 0.88 | TACR2 (0.58) | TACR2NPY5RFPR2S1PR1 | |
| SCHEMBL8297811 | 0.86 | NPY5R (0.47) | UTS2RTACR2NPY5RS1PR1 | |
| SCHEMBL5406371 | 0.86 | NPY5R (0.47) | UTS2RTACR2NPY5RS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | claimed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | UTS2R 855/4885TACR2 1302/4885NPY5R 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.